PFNX Pfenex Inc.

11.59
+0.45  (+4%)
Previous Close 11.14
Open 10.72
Price To Book 6.58
Market Cap 366,965,336
Shares 31,675,903
Volume 138,210
Short Ratio 1.65
Av. Daily Volume 315,009
Stock charts supplied by TradingView

NewsSee all news

  1. Serum Institute of India Private Limited has achieved World Health Organization (WHO) prequalification for PNEUMOSIL®, containing CRM197 produced in Pfenex Expression Technology

    SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE:PFNX) today announced that Serum Institute of India Private Limited (Serum Institute) achieved World Health Organization (WHO) prequalification for

  2. Pfenex Earns $15 Million Development Milestone Under its Development and License Agreement With Jazz Pharmaceuticals

    SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE:PFNX) today announced that it has earned a $15 million development milestone under its development and license agreement with Jazz Pharmaceuticals plc. The

  3. Pfenex to Present at the Piper Jaffray 31st Annual Healthcare Conference

    SAN DIEGO, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE:PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and improve protein therapies

  4. Pfenex to Present at the Evercore ISI HealthCONx Conference 2019

    SAN DIEGO, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE:PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and improve protein therapies

  5. Pfenex Announces Management Change

    SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE:PFNX), today announced that Susan Knudson has resigned for personal reasons from her role as Senior Vice President, Chief Financial Officer effective

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA approval announced October 7, 2019.
PF708
Osteoporosis
Phase 2 trial to be initiated 2019 subject to funding.
Px563L
Anthrax vaccine
NDA filing submitted January 21, 2020.
JZP-258
Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
Phase 1/2 data released August 2016. Noted November 9, 2017 that development has been paused until strategic partnerships are forged.
PF582
Biosimilar candidate to Lucentis for retinal diseases
Phase 3 trial of partnered product met primary endpoint - March 6, 2019.
CRM197
Pneumococcal conjugate vaccine
Phase 2/3 commencement of enrolment announced December 30, 2019.
JZP-458
Acute lymphoblastic leukemia (ALL)
Phase 3 data possibly due by end of 2019 or early 2020.
PCV-15 (V114)
Pneumococcal disease

Latest News

  1. Serum Institute of India Private Limited has achieved World Health Organization (WHO) prequalification for PNEUMOSIL®, containing CRM197 produced in Pfenex Expression Technology

    SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE:PFNX) today announced that Serum Institute of India Private Limited (Serum Institute) achieved World Health Organization (WHO) prequalification for

  2. Pfenex Earns $15 Million Development Milestone Under its Development and License Agreement With Jazz Pharmaceuticals

    SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE:PFNX) today announced that it has earned a $15 million development milestone under its development and license agreement with Jazz Pharmaceuticals plc. The

  3. Pfenex to Present at the Piper Jaffray 31st Annual Healthcare Conference

    SAN DIEGO, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE:PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and improve protein therapies

  4. Pfenex to Present at the Evercore ISI HealthCONx Conference 2019

    SAN DIEGO, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE:PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and improve protein therapies

  5. Pfenex Announces Management Change

    SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE:PFNX), today announced that Susan Knudson has resigned for personal reasons from her role as Senior Vice President, Chief Financial Officer effective

  6. Pfenex Reports Third Quarter 2019 Results and Provides Business Update

    Received U.S. FDA approval for PF708 to treat osteoporosis and submitted comparative use human factors (HF) study report to FDA; Commercial launch by Alvogen expected upon FDA decision on the therapeutic equivalence

  7. Pfenex to Present at the Jefferies 2019 London Healthcare Conference

    SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE:PFNX) today announced that Eef Schimmelpennink, President and Chief Executive Officer, will be presenting at the Jefferies 2019 London Healthcare

  8. Pfenex Reports Positive Results for PF708 Comparative Use Human Factors Study

    Study results found that the FDA-approved PF708 product is noninferior to Forteo® based on a pre-specified statistical analysis of critical patient and caregiver tasks Pfenex believes the study report completes the

  9. Pfenex Provides Update for PF708 Outside the United States

    New Exclusive Commercialization Agreements in South Korea, Canada, and Israel Submission of Marketing Authorization Application for PF708 in Saudi Arabia Potential approval of PF708 in the EU as early as the second

  10. Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis

    Pfenex earns a $2.5M milestone payment from Alvogen for U.S. approval Comparative human factors study report expected to be submitted to FDA as early as the second half of October 2019 SAN DIEGO, Oct. 07, 2019 (GLOBE

  11. Pfenex to Present at the Cantor Healthcare Conference

    SAN DIEGO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE:PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein

  12. Pfenex to Participate in the Oppenheimer Fall Summit

    SAN DIEGO, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE:PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein

  13. Pfenex Earns $11 Million Development Milestone under its Development and License Agreement with Jazz Pharmaceuticals

    SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE:PFNX) today announced that it has earned an $11 million development milestone under its development and license agreement with Jazz Pharmaceuticals. The

  14. Pfenex Appoints Dr. Steve Kay to Scientific Advisory Board

    SAN DIEGO, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE:PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein